wade king
chief executive officer
prota therapeutics
Dr. Wade King was appointed chief executive officer of Prota Therapeutics in February of 2019. Wade brings highly successful, senior roles across multiple facets of the health care industry to the company.
Previously, Wade was chief of anesthesiology for a 20-physician practice in Silicon Valley. During his clinical years Wade became an expert in drug delivery and consulted frequently to the venture capital community regarding early stage health care investments.
Following Stanford Business School, Wade went on to become a repeat Wall Street Journal all-star health care analyst and director of investment research for multiple investment banks. Subsequently, Wade was senior portfolio manager and COO at investment management firms. Wade then went on to multiple senior operating roles in biotechnology companies. He led both finance and business development for Neomend, a surgical sealant company that was acquired by CR Bard, now part of Becton Dickinson. Subsequently, Wade led corporate development and strategy and served on the management team of Insmed, a multi-billion dollar public rare disease company. While at Insmed, Wade led the exclusive global licensing of a novel DPP1 inhibitor from Astra Zeneca in a deal worth potentially hundreds of millions of dollars. Wade is a board-certified anesthesiologist and completed residencies in Surgery and Anesthesiology at UCSF.
Wade holds an M.S.M. from Stanford Business School, M.D. and M.P.H. degrees from UNC Chapel Hill Schools of Medicine and Public Health, and a B.A., cum laude, from Princeton University.
Learn more about Wade: https://www.linkedin.com/in/wadeking/